Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Vertex Pharmaceuticals slipped 1.41% to close at $475.49, managing to outperform a much gloomier market where the S&P 500 nose-dived 3.46%. Despite the drop, Vertex flexed its resilience, outpacing ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer looked at recently. Jim Cramer, the host of Mad ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex Pharmaceuticals is discontinuing a buzzy diabetes therapy and with it, taking a $400 million impairment charge. The drug-device combo was part of the company’s diabetes portfolio that has been ...